Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination

NCT01973868 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: Regorafenib (Stivarga, BAY73-4506)
DRUG: Cetuximab (ERBITUX)

Sponsor

Bayer